Acino Holding AG (XSWX:ACIN) Debt-to-EBITDA : 3.46 (As of Dec. 2013)

View and export this data going back to . Start your Free Trial

What is Acino Holding AG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Acino Holding AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was CHF15.1 Mil. Acino Holding AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2013 was CHF117.4 Mil. Acino Holding AG's annualized EBITDA for the quarter that ended in Dec. 2013 was CHF38.3 Mil. Acino Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2013 was 3.46.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Acino Holding AG's Debt-to-EBITDA or its related term are showing as below:

XSWX:ACIN's Debt-to-EBITDA is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.66
* Ranked among companies with meaningful Debt-to-EBITDA only.

Acino Holding AG Debt-to-EBITDA Historical Data

The historical data trend for Acino Holding AG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acino Holding AG Debt-to-EBITDA Chart

Acino Holding AG Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-EBITDA

Get a 7-Day Free Trial

3.43

3.46

Acino Holding AG Semi-Annual Data
	Dec03	Dec04	Dec05	Dec06	Dec07	Dec08	Dec09	Dec10	Dec11	Dec12	Dec13
Debt-to-EBITDA	Get a 7-Day Free Trial						-	-	-	3.43	3.46

Competitive Comparison of Acino Holding AG's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Acino Holding AG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acino Holding AG's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Acino Holding AG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Acino Holding AG's Debt-to-EBITDA falls into.

Acino Holding AG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Acino Holding AG's Debt-to-EBITDA for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(15.06	+	117.351)	/	38.301
	=	3.46

Acino Holding AG's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2013 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(15.06	+	117.351)	/	38.301
	=	3.46

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2013) EBITDA data.

Acino Holding AG (XSWX:ACIN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Acino Holding AG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Acino Holding AG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Acino Holding AG (XSWX:ACIN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acino Holding AG (XSWX:ACIN) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Website

http://www.acino-pharma.com

Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.

Acino Holding AG (XSWX:ACIN) Headlines

No Headlines